Tiziana Life Sciences Ltd.: Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

- Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response - FDA allows for continued enrollment under

Related Keywords

Boston ,Massachusetts ,United States ,United Kingdom ,Harvard University ,Kunwar Shailubhai ,Irina Koffler ,Howard Weiner ,Gabriele Cerrone ,Tanuja Chitnis ,Lifesci Advisors ,Drug Administration ,Tiziana Life Sciences ,Professor Of Neurology At Harvard Medical School ,Tiziana Life Sciences Nasdaq ,Patient Expanded Access Program ,Sclerosis Program ,Individual Patient Expanded Access ,Life Sciences ,Chief Executive Officer ,Positron Emission Tomography ,Expanded Disability Status Scale ,Multiple Sclerosis Program ,Scientific Advisory Board ,Principal Investigator ,Harvard Medical School ,Massachusetts General Hospital ,Sci Advisors ,Tiziana ,Life ,Ciences ,Enrolls ,Second ,Patient ,Ngoing ,Intranasal ,Foralumab ,Evaluation ,Secondary ,Progressive ,Multiple ,Clerosis ,